Positive study results in 298 patients with obstructive sleep apnea (OSA): Significant reduction of nocturnal breathing pauses with an oral investigational medicinal product after 15 weeks of treatment.
Desitin Acquires Rights on Orphan Drug in CNS for Europe
Desitin Arzneimittel GmbH has signed an exclusive License Agreement to commercialize an orphan drug being developed by AFT Pharmaceuticals, a specialist pharmaceutical company based in Auckland, New Zealand, to treat facial angiofibromas, a symptom of Tuberous Sclerosis Complex (TSC).
Desitin Arzneimittel GmbH is a European pharmaceutical company. We are specialized in sophisticated products for the therapy of neurological and psychiatric diseases. We also have affiliates in 9 European countries.
